Hospital

Kate Smullen, PharmD, CSP, MSCS, senior director of clinical services at Shields Health Solutions, discussed her journey to becoming a pharmacist and how she has been celebrating this American Pharmacists Month.

Amber Bush, PharmD, RPh, BCPS, BCCCP, pharmacy research coordinator for Mayo Clinic discusses the future of pharmacy through her role within research clinical trials

Ramesh Cheruvu, PharmD, pharmacist and pharmacy manager at Health Mart Family Pharmacy at McKesson, discussed his journey in the pharmaceutical industry and how it has changed since he became a pharmacist.

RFID technology encompass a wide range of applications, including inventory management, medication authentication, patient adherence, and workflow efficiency.

Study finds that probable insomnia disorder was associated with physical health problems and difficulty with anger in veterans.

However, uncomplicated diabetes was not significantly linked to a greater risk of all-cause mortality or death from colorectal cancer.

With a new administration protocol created specifically for the routine clinic, infectious disease physicians can treat recurrent clostridioides difficile infection in less than 3 weeks.

Although everyone’s residency looks different, it is important for mothers to assess childcare options, be transparent about their schedule, and take care of themselves.

Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.

Christina Barrington, PharmD, vice president of pharmacy programs at Priority Health, discusses current disruptors in the marketplace and high-cost drugs.

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.

A critical aspect of National Prescription Drug Take Back Day is the focus on Naloxone training.

Semaglutide was found to be the most effective drug for weight loss, but the benefits may not outweigh the cost associated with treatment.

The drug’s mode of action is different than other types of corticosteroids because it’s based in the differential effects on glucocorticoid and mineralocorticoid receptors.

The vice president of pharmacy operations at American Oncology Network discusses the 340B Drug Pricing Program and its growth and impact on community oncology.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses SDOH and how pharmacists, particularly within community pharmacies, are the most accessible health care providers and can play a crucial role in advocating for patients.

The hybrid pharmacy model represents a significant step forward in providing the best possible care for individuals struggling with behavioral health conditions, ultimately improving their outcomes and overall well-being.

Pharmacists can leverage their own identities to advocate for happier, healthier individuals within communities of different ethnic and socioeconomic backgrounds

Craig Sastic, PharmD, MBA, BCPS, discussed how he has seen the pharmacy field change throughout his career.

With health systems undergoing a necessary reevaluation of how they allocate their funding into the future, initial data support the need for them to offer a hospital-at-home option for patients they serve.

From finding mentors to maintaining a balanced lifestyle, these insights will empower students to navigate the ever-evolving world of pharmacy.

Confident pharmacists have traits that highlight their professionalism and effectiveness in their roles, while avoiding behaviors that could undermine the quality of their work.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Vosoritide is a daily injection for children with achondroplasia who have open epiphyses, given under the skin and administered by a caregiver.

Viktor Grunwald, MD, PhD, discusses the post-hoc analysis of the phase 3 CLEAR trial investigating the combination treatment in the first-line setting for advanced renal cell carcinoma.

Compared to chemotherapy alone, amivantamab plus chemotherapy treatment with and without lazertinib had also demonstrated positive trends in OS and ORR in patients with NSCLC.

Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.

Many patients face significant challenges in accessing their specialty medications, which highlights the importance of pharmacy-deployed patient navigation programs designed to help resolve nonclinical, system-related barriers to care.

Patients with previously untreated HLA-A*02:01+ mUM saw improvements in OS, PFS, and ctDNA clearance.